Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder

NCT01414114 is registered in ClinicalTrials.gov with KAI Pharmaceuticals as lead sponsor.

NCT NCT01414114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01414114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder
Lead sponsor
KAI Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 5, 2011
Completion date
May 21, 2012
Enrollment
37 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism